543910-49-2 Usage
Uses
Used in Pharmaceutical Industry:
Tert-butyl octahydro-4-hydroxyindole-1-carboxylate is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique structure and properties make it a valuable component in the synthesis of a wide range of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical industry, tert-butyl octahydro-4-hydroxyindole-1-carboxylate is utilized as a synthetic intermediate for the development of agrochemicals. Its specific properties allow for the creation of various chemical compounds that can be used in the production of pesticides, herbicides, and other agricultural chemicals, enhancing crop protection and yield.
Used in Organic Synthesis:
Tert-butyl octahydro-4-hydroxyindole-1-carboxylate is employed as a key component in organic synthesis for the creation of diverse chemical compounds. Its unique structure and the presence of the tert-butyl group make it a versatile building block for the synthesis of various organic molecules, contributing to the advancement of chemical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 543910-49-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,4,3,9,1 and 0 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 543910-49:
(8*5)+(7*4)+(6*3)+(5*9)+(4*1)+(3*0)+(2*4)+(1*9)=152
152 % 10 = 2
So 543910-49-2 is a valid CAS Registry Number.
InChI:InChI=1/C13H23NO3/c1-13(2,3)17-12(16)14-8-7-9-10(14)5-4-6-11(9)15/h9-11,15H,4-8H2,1-3H3
543910-49-2Relevant articles and documents
ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR
-
Paragraph 0208; 0214; 0215, (2017/06/12)
The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.
AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: Identification, SAR and pharmacological characterization
Vranesic, Ivo,Ofner, Silvio,Flor, Peter Josef,Bilbe, Graeme,Bouhelal, Rochdi,Enz, Albert,Desrayaud, Sandrine,McAllister, Kevin,Kuhn, Rainer,Gasparini, Fabrizio
, p. 5790 - 5803 (2015/01/09)
Here we describe the identification, structure-activity relationship and the initial pharmacological characterization of AFQ056/mavoglurant, a structurally novel, non-competitive mGlu5 receptor antagonist. AFQ056/mavoglurant was identified by chemical der